Athena Athena

X
[{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"Moleculin Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"ADC Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ADC Therapeutics\u2019 ZYNLONTA Added to National Comprehensive Cancer Network\u00ae Clinical Practice Guidelines in Oncology for B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Sterling Pharma Solutions","sponsor":"OncoTEX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoTEX and Sterling Pharma Solutions Sign Clinical Manufacturing Agreement for the Development of Novel Treatment Against Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Sterling Pharma Solutions Limited

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers. Under the terms of the agreement, Sterling will produce clinical material in its cGMP facility in Germantown, Wisconsin.

            Lead Product(s): Oxaliplatin,Texaphryn

            Therapeutic Area: Oncology Product Name: OxaliTEX

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: OncoTEX

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement May 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The NCCN Guidelines now include ZYNLONTA as a category 2A designation as a treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

            Lead Product(s): Loncastuximab tesirine-lpyl

            Therapeutic Area: Oncology Product Name: Zynlonta

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: ADC Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Moleculin Biotech has signed an agreement with Sterling Pharma for US production of WP1122 to support its expanded development efforts in preparation for submitting a request to the US FDA for Investigational New Drug status for WP1122 for the potential treatment of COVID-19.

            Lead Product(s): WP1122

            Therapeutic Area: Infections and Infectious Diseases Product Name: WP1122

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Moleculin Biotech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 15, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY